IDEAS home Printed from https://ideas.repec.org/a/eee/hepoli/v94y2010i3p221-229.html
   My bibliography  Save this article

Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment

Author

Listed:
  • Wettermark, Björn
  • Godman, Brian
  • Neovius, Martin
  • Hedberg, Niklas
  • Mellgren, Tor-Olov
  • Kahan, Thomas

Abstract

Objective The Swedish Dental and Pharmaceutical Benefits Agency is re-assessing the value of all drugs included in the reimbursement scheme in order to make the most efficient use of resources. Their recent review of antihypertensive drugs included 46 substances with total annual sales of [euro]230 million ([euro]25/capita). This resulted in reimbursement restrictions for 26 substances, e.g. all angiotensin receptor blockers (ARBs).Methods We used the Swedish prescribed drug register to evaluate the initial effects on prescribing patterns using a before-and-after design, comparing utilization and expenditure with corresponding periods previous years.Results The proportion of the Swedish population being dispensed antihypertensive drugs increased by 0.5%-units to 16.5% in September-December 2008 compared to the same period in 2007. Patients initiated on ARBs decreased by 24%, whilst increasing for ACE inhibitors (ACEI) and calcium channel blockers, by 14% and 12%, respectively. The proportion initiated on ARBs prescribed an ACEI within 24 months prior to an ARB increased from 51% to 67%, with a substantial regional variation (extremal quotient 31; coefficient of variation 36%). The total expenditure decreased by 4.7% to [euro]73 million in September-December 2008 compared to the same period in 2007.Conclusions Reimbursement restrictions had a positive impact on enhancing the efficiency of antihypertensive prescribing. Resources released can be used to improve care in the future.

Suggested Citation

  • Wettermark, Björn & Godman, Brian & Neovius, Martin & Hedberg, Niklas & Mellgren, Tor-Olov & Kahan, Thomas, 2010. "Initial effects of a reimbursement restriction to improve the cost-effectiveness of antihypertensive treatment," Health Policy, Elsevier, vol. 94(3), pages 221-229, March.
    • Handle: RePEc:eee:hepoli:v:94:y:2010:i:3:p:221-229
    as

    Download full text from publisher

    File URL: http://www.sciencedirect.com/science/article/pii/S0168-8510(09)00257-7
    Download Restriction: Full text for ScienceDirect subscribers only
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Anders Anell, 2005. "Swedish healthcare under pressure," Health Economics, John Wiley & Sons, Ltd., vol. 14(S1), pages 237-254, September.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Pettersson, Billie & Hoffmann, Mikael & Andersson, David & Wändell, Per & Levin, Lars-Åke, 2012. "Utilization and costs of glucose lowering therapies following health technology assessment for the new reimbursement scheme in Sweden," Health Policy, Elsevier, vol. 108(2), pages 207-215.
    2. Pichetti, Sylvain & Sorasith, Christine & Sermet, Catherine, 2011. "Analysis of the impact of removing mucolytics and expectorants from the list of reimbursable drugs on prescription rates: A time-series analysis for France 1998–2010," Health Policy, Elsevier, vol. 102(2), pages 159-169.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Samantha Smith, 2010. "The Irish ‘health basket’: a basket case?," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 11(3), pages 343-350, June.
    2. Cecilia Gardsten & Kerstin Blomqvist & Mikael Rask & Åse Larsson & Agneta Lindberg & Gith Olsson, 2018. "Challenges in everyday life among recently diagnosed and more experienced adults with type 2 diabetes: A multistage focus group study," Journal of Clinical Nursing, John Wiley & Sons, vol. 27(19-20), pages 3666-3678, October.
    3. Joan Costa-i-Font & Valentina Zigante, 2014. "The Choice Agenda' in European Health Systems: The Role of 'Middle Class Demands," LEQS – LSE 'Europe in Question' Discussion Paper Series 82, European Institute, LSE.
    4. Hjelmgren, Jonas & Anell, Anders, 2007. "Population preferences and choice of primary care models: A discrete choice experiment in Sweden," Health Policy, Elsevier, vol. 83(2-3), pages 314-322, October.
    5. Stefan Meyer, 2015. "Payment schemes and cost efficiency: evidence from Swiss public hospitals," International Journal of Health Economics and Management, Springer, vol. 15(1), pages 73-97, March.
    6. Joan Costa-Font & Valentina Zigante, 2016. "The choice agenda in European health systems: the role of middle-class demands," Public Money & Management, Taylor & Francis Journals, vol. 36(6), pages 409-416, September.
    7. Kristian Bolin & Anna Lindgren & Björn Lindgren & Petter Lundborg, 2009. "Utilisation of physician services in the 50+ population: the relative importance of individual versus institutional factors in 10 European countries," International Journal of Health Economics and Management, Springer, vol. 9(1), pages 83-112, March.
    8. Toth, Federico, 2010. "Healthcare policies over the last 20 years: Reforms and counter-reforms," Health Policy, Elsevier, vol. 95(1), pages 82-89, April.
    9. Ulf-G Gerdtham & Philip Clarke & Alison Hayes & Soffia Gudbjornsdottir, 2009. "Estimating the Cost of Diabetes Mellitus-Related Events from Inpatient Admissions in Sweden Using Administrative Hospitalization Data," PharmacoEconomics, Springer, vol. 27(1), pages 81-90, January.
    10. d'Andria, Diego, 2008. "The Debate on the Sustainability of Social Spending," MPRA Paper 11745, University Library of Munich, Germany.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:eee:hepoli:v:94:y:2010:i:3:p:221-229. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Catherine Liu or the person in charge (email available below). General contact details of provider: http://www.elsevier.com/locate/healthpol .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.